HLA Class I genotype is associated with relapse risk after allogeneic stem cell transplantation for NPM1-mutated AML.

[1]  R. Majeti,et al.  Reprogramming Cancer into Antigen Presenting Cells as a Novel Immunotherapy. , 2021, Cancer discovery.

[2]  R. Krance,et al.  Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant. , 2020, Blood.

[3]  Andrew R. Jones,et al.  A snapshot of human leukocyte antigen (HLA) diversity using data from the Allele Frequency Net Database. , 2020, Human immunology.

[4]  Jianzhu Chen,et al.  CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia , 2020, Nature Biomedical Engineering.

[5]  Alex Rubinsteyn,et al.  MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing. , 2020, Cell systems.

[6]  M. Carrington,et al.  HLA-B Leader and Survivorship after HLA-Mismatched Unrelated Donor Transplantation. , 2020, Blood.

[7]  Jiangning Song,et al.  A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction , 2020, Briefings Bioinform..

[8]  Bjoern Peters,et al.  Benchmarking predictions of MHC class I restricted T cell epitopes in a comprehensively studied model system , 2020, PLoS Comput. Biol..

[9]  D. Bunjes,et al.  Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients , 2019, Journal of clinical medicine.

[10]  Lauren L. Ritterhouse,et al.  High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia , 2019, American journal of hematology.

[11]  Lisa E. Wagar,et al.  Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin , 2019, PloS one.

[12]  N. Potter,et al.  Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study. , 2019, Blood.

[13]  N. Munshi,et al.  Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy , 2019, Leukemia.

[14]  R. Hagedoorn,et al.  Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia , 2019, The Journal of clinical investigation.

[15]  B. Falini,et al.  Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia , 2019, Oncotarget.

[16]  J. Esteve,et al.  Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remission , 2018, American journal of hematology.

[17]  N. Potter,et al.  Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status , 2018, Blood.

[18]  Alessandro Sette,et al.  The Immune Epitope Database (IEDB): 2018 update , 2018, Nucleic Acids Res..

[19]  Alex Rubinsteyn,et al.  MHCflurry: Open-Source Class I MHC Binding Affinity Prediction. , 2018, Cell systems.

[20]  T. Graubert,et al.  High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. , 2018, Blood.

[21]  M. Nielsen,et al.  NetMHCpan-4.0: Improved Peptide–MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data , 2017, The Journal of Immunology.

[22]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[23]  M. Mann,et al.  Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry , 2016, Nature Communications.

[24]  Yashma Patel,et al.  Assessment of Minimal Residual Disease in Standard-Risk AML. , 2016, The New England journal of medicine.

[25]  J. Esteve,et al.  Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status , 2016, Haematologica.

[26]  B. Brodská,et al.  Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia , 2015, PloS one.

[27]  N. Schmitz,et al.  Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Carrington,et al.  HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. , 2014, Blood.

[29]  J. Esteve,et al.  Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT , 2014 .

[30]  M. Aljurf,et al.  Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. , 2014, Blood.

[31]  J. Klein,et al.  Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. , 2013, Blood.

[32]  H. Döhner,et al.  Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  K. Döhner,et al.  Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. , 2012, Blood.

[34]  Baoan Chen,et al.  Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. , 2010, Experimental hematology.

[35]  Bjoern Peters,et al.  HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.

[36]  Philip E. Bourne,et al.  The Immune Epitope Database and Analysis Resource , 2006, PRIB.

[37]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[38]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.